中华医学杂志（英文版）2009，Vol.122Issue(1)：88-92,5.DOI:10.3760/cma.j.issn.0366-6999.2009.01.016
Clinical outcomes of serolimus-eluting stents versus bare metal stents in ST-segment elevation myocardial infarction patients: a meta-analysis
Clinical outcomes of serolimus-eluting stents versus bare metal stents in ST-segment elevation myocardial infarction patients: a meta-analysis
PAN Xiao-hong 1ZHONG Wen-zhao 1XIANG Mei-xiang 2XU Geng 1SHAN Jiang 1WANG Jia-nan1
作者信息
- 1. Department of Cardiology, 2nd Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009,China
- 2. Lung Cancer Research Institute & Cancer Center, Guangdong Provincial People's Hospital, Guangzhou, Guangdong 510080, China
- 折叠
摘要
Abstract
Background The benefits and safety of sirolimus-eluting stent (SES) have not been systematically quantified in different trials in ST-segment elevation myocardial infarction (STEMI) patients with primary or rescue percutaneous coronary intervention (PCI). A meta-analysis of randomised trials comparing SES and bare-metal stent (BMS) was performed. Methods A systematic literature search was conducted to identify all randomized clinical trials. The primary outcome was the rate of major adverse cardiac events (MACEs). The secondary outcomes included death, recurrent myocardial infarction, recurrent revascularization, and stent thrombosis. Results Totally, 1973 STEMI patients were enrolled in seven eligible randomized trials comparing SES with BMS. The pooled rate of major adverse cardiac events was significantly lower in the SES group than in the BMS group (9.7% vs 20.3%, OR 2.45, 95% Cl 1.88-3.19, P < 0.00001). No significant difference in all causes of death was found between the SES and BMS groups, as well as in the pooled recurrent myocardial infarction rates. The pooled recurrent revascularization rate was significantly lower in the SES group than in the BMS group (5.1% vs 14.8%, OR 3.30, 95%Cl 2.37-4.60, P < 0.00001). No significant difference was found between the pooled rates of stent thrombosis (1.2% in the SES group and 2.0% in the BMS group, OR 1.61, 95%Cl 0.79-3.26, P=0.19). Conclusions SES is associated with a decreased risk of major adverse cardiac events compared with BMS by thegreater reduction in repeat revascularization in STEMI patients. Larger trials with longer follow up are warranted to betterdefine the role of SES in STEMI.关键词
- myocardial infarction/sirolimus-eluting stents/bare-metal stentsKey words
- myocardial infarction/sirolimus-eluting stents/bare-metal stents分类
医药卫生引用本文复制引用
PAN Xiao-hong,ZHONG Wen-zhao,XIANG Mei-xiang,XU Geng,SHAN Jiang,WANG Jia-nan..Clinical outcomes of serolimus-eluting stents versus bare metal stents in ST-segment elevation myocardial infarction patients: a meta-analysis[J].中华医学杂志（英文版）,2009,122(1):88-92,5.
